A second aspect of this study explored the use of various molecular markers measured on the breast tumor to predict the added value of chemotherapy. The purpose of this was to determine if the individual's biologic profile on an individual tumor enables us to tailor therapy more specifically.
"These results will help current breast cancer treatment in that we are moving to regimens tailored to the specific individual's cancer and it will stimulate future research," said Albain.
Co-authors of the study are K. S. Albain; W. Barlow; F. O'Malley; K Siziopikou; I-T Yeh; P. Ravdin; D. Lew; W. Farrar; G. Burton; S. Ketchel; C. Cobau; E. Levine; J. Ingle; K. Pritchard; A. Lichter; D. Schneider; M. Abeloff; I. C. Henderson; L. Norton; D. Hayes; S. Green; R. Livingston; S. Martino; C. K. Osborne; and D. C. Allred, The Breast Cancer Intergroup of North America, Loyola University Chicago Stritch School of Medicine, Maywood, Ill.
For more information on Loyola University Health System, log onto http://www.luhs.org
The 27th Annual San Antonio Breast Cancer Symposium meeting at the Henry B. Gonzalez Convention Center, San Antonio, Tex., runs through December 11, 2004.
'"/>
Contact: Joanne Swanson
jswanson@lumc.edu
708-216-2445
Loyola University Health System
8-Dec-2004